Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Heart-thigh cuff pulse wave velocity (htPWV) represents a promising, user-independent technique for noninvasive estimation of aortic stiffness, though further validation against invasive standards and outcome data are needed.
The assessment of the pulse waveform, as a tool for diagnosis, has attracted interest for many hundreds of years, because it was recognized very early that arterial elasticity is related to characteristics of the pressure pulse waveform and the velocity of its propagation through the arterial tree. With the emergence of sophisticated computers and software, novel noninvasive methods of assessing arterial stiffness have been developed, hailing the modern era of arterial pulse wave assessment. Studies conducted by many investigators around the world have now generated an impressive body of evidence demonstrating the importance of large artery stiffness in our understanding of cardiovascular disease (CVD) risk. Increased aortic stiffness is associated with cardiovascular risk factors such as hypertension, hyperlipidemia, and diabetes,1 underlining its role as an important biomarker of disease. However, it is also likely that aortic stiffening drives various disease processes and is an important risk factor in itself. Indeed, aortic pulse wave velocity (PWV), a robust index of aortic stiffness, independently predicts future fatal and nonfatal CVD events and all-cause mortality.2 As such, aortic PWV adds value to risk prediction beyond that provided by traditional cardiovascular risk factors and improves risk classification. But despite these data, the widespread adoption of aortic PWV into routine clinical assessment has yet to be realized. The gold-standard method of assessing aortic PWV is undoubtedly via a pressure-sensing catheter sited within the aorta itself. However, as has been stated many times previously, this method is simply not feasible for the routine clinical assessment of aortic stiffness. Fortunately, aortic PWV can be estimated, noninvasively, using a number of different approaches. By far the most established of these is the carotid–femoral PWV (cfPWV), where pulse waves are recorded at carotid and femoral artery sites, allowing calculation of the pulse wave transit time between them. Estimation of the distance between recording sites allows calculation of the PWV. A number of commercially available devices have been developed and marketed for the assessment of cfPWV, together with other waveform features, using various approaches such as applanation tonometry (SphygmoCor, AtCor Medical, Sydney, Australia, PulsePen, DiaTecne s.r.l., Milan, Italy, VP-1000 Plus/2000 Plus, Omron Healthcare, Kyoto, Japan), mechanotransducers (Complior, Alam Medical, Saint Quentin Fallavier, France), volume displacement (Vicorder, Skidmore Medical, Bristol, UK), or a combination of these methods (SphygmoCor XCEL, AtCor Medical). Refer to Milan et al.3 for a comprehensive review of validation studies for these and similar techniques. All of these devices are relatively simple to use, although some do require more training and practice than others. They are also highly portable and suitable for obtaining cfPWV measurements in large numbers of individuals. Moreover, the devices have been validated extensively, including against invasively determined aortic PWV,3,4 leading to the acceptance of cfPWV as the reference standard for noninvasive assessments of aortic stiffness. However, there is still a degree of technical skill required to obtain high-quality waveforms reliably at the carotid and femoral sites. Moreover, exposure of the groin with non-cuff-based approaches is problematic for some participants. There are also other, subtler, technical issues with the assessment of cfPWV. Typically, the carotid-to-femoral path length is calculated by subtracting the suprasternal-notch-to-carotid distance from the suprasternal-notch-to-femoral distance,5 to account for the fact that the pulse wave travels along the carotid artery and the thoracic aorta simultaneously. This can result in difficulties in establishing the “true” path length, although the “subtraction method” compares favorably to actual path length measured via magnetic resonance imaging.6 Moreover, cfPWV measurements include segments of the brachiocephalic trunk and carotid, iliac, and femoral arteries, which are stiffer than the aorta, potentially leading to overestimation of the true aortic PWV. Furthermore, measurements of cfPWV omit the aortic arch, which is highly elastic and most likely affects the true aortic PWV. Therefore, although the value of cfPWV in cardiovascular risk assessment has been recognized, aspects of the measurement technique can still be improved. With this in view, the drive to develop further novel techniques and devices to assess aortic stiffness has intensified in recent years. One interesting development has been the introduction of devices that allow “single-point” assessments of aortic PWV from a waveform recording at the brachial artery, using an oscillometric cuff. The Arteriograph (Tensiomed, Budapest, Hungary),7 BPLab (Petr Telegin, Nizhny Novgorod, Russia),8 and Mobil-O-Graph (IEM GmbH, Stolberg, Germany)9 all utilize this approach, and are very simple to use and highly operator-independent, representing a considerable advance in technology, which is potentially suitable for widespread clinical uptake. However, as a note of caution, the measurement principles and/or algorithms employed by these devices have been criticized,4,10,11 and so their role in cardiovascular risk assessment has yet to be firmly established. A more traditional approach is calculation of the heart-to-femoral PWV (hfPWV), representing the PWV between the origin of the aorta and the femoral artery. This method is not particularly new, having been first proposed by Hasegawa12 in 1970, but hfPWV overcomes one of the limitations of cfPWV measurements in that the brachiocephalic trunk and common carotid artery are excluded, whereas the ascending aorta is included in the PWV path. Therefore, hfPWV may actually provide a better estimation of the true aortic PWV than measurements of cfPWV. Heart–femoral PWV is associated with various cardiovascular risk factors13–15 and a higher incidence of CVD,16 supporting its potential importance as a cardiovascular risk assessment tool. Nevertheless, the technique still involves applanation tonometry of the femoral artery and, thus, exposure of the groin, which may cause discomfort to some participants. In this issue of the Journal, Fico et al.17 highlight a new possibility for both an operator- and recipient-friendly technique for accurate, noninvasive estimation of aortic PWV. They used a modified version of the VaSera system (Fukuda Denshi, Tokyo, Japan), better known for measuring cardio-ankle PWV and calculation of the pressure-independent cardio-ankle vascular index.18 However, rather than an ankle cuff, this iteration of the VaSera device uses a thigh cuff, similar to the Vicorder and SphygmoCor XCEL devices, bypassing the need for femoral artery tonometry. Measurements of heart–thigh cuff PWV (htPWV) were compared with cfPWV obtained with the VP-1000 Plus device. On first impressions, the htPWV method looks set to achieve the best of both worlds: a potentially more accurate estimate of the true aortic PWV, but with an unobtrusive, user-independent approach. However, although promising, the htPWV method requires further validation and some improvement. First, although acceptable correlation and agreement between htPWV and cfPWV were demonstrated, it would be useful to compare htPWV to cfPWV obtained with other widely used noninvasive PWV measurement devices, and direct comparison with invasively determined aortic PWV is certainly warranted. Second, estimation of the pulse wave path length is unquestionably important in the measurement of aortic PWV. The distance measurement used in the study by Fico et al.17 (left sternal border of second intercostal space to palpable point of right femoral artery) does not appear to include the ascending aorta in the path length, which may lead to an underestimation of htPWV. Indeed, the original description of hfPWV by Hasegawa12 multiplied the left sternal-femoral distance by 1.3, and, therefore, further work may be required to validate the path length used in the current calculation of htPWV. Third, in the study by Fico et al.,17 htPWV showed a substantially weaker correlation with age than cfPWV (r = 0.58 vs. r = 0.80). The authors cited the study by Hickson et al.19 in explaining that the inclusion of a longer segment of femoral artery in the htPWV measurement may have weakened the correlation with age, because the stiffness of the muscular femoral artery remains relatively constant with aging. Of note, it may be possible to mathematically correct the htPWV19 and thus improve further the accuracy of the method. Finally, data demonstrating that htPWV can predict outcomes independently of other cardiovascular risk factors would firmly establish the validity of this technique for cardiovascular risk assessment. Ultimately, the widespread acceptance of aortic PWV as a risk assessment tool is likely to depend on data demonstrating that outcomes are improved when risk stratification and/or treatment decisions are based on knowledge of the aortic PWV. Such studies are therefore necessary, but are likely to be time-consuming and expensive, and will depend on the availability of measurement techniques that require little technical skill and are acceptable to clinicians and patients alike. In this regard, htPWV represents a promising step along the path toward the adoption of aortic PWV measurement in routine clinical practice. The authors declared no conflict of interest. This work was funded, in part, by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (Grant No. RG85315). The views expressed are those of the authors and not necessarily those of the NIHR. The authors appreciate the financial support provided by China Scholarship Council (CSC; Grant No. 201806260070) for S.Y.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: